Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,960 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial.
Tanaka Y, Oba K, Koike T, Miyasaka N, Mimori T, Takeuchi T, Hirata S, Tanaka E, Yasuoka H, Kaneko Y, Murakami K, Koga T, Nakano K, Amano K, Ushio K, Atsumi T, Inoo M, Hatta K, Mizuki S, Nagaoka S, Tsunoda S, Dobashi H, Horie N, Sato N. Tanaka Y, et al. Among authors: nakano k. Ann Rheum Dis. 2020 Jan;79(1):94-102. doi: 10.1136/annrheumdis-2019-216169. Epub 2019 Oct 19. Ann Rheum Dis. 2020. PMID: 31630117 Free PMC article. Clinical Trial.
Abatacept ameliorates both glandular and extraglandular involvements in patients with Sjögren's syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren's Syndrome Endocrinopathy) and ROSE II trials.
Tsuboi H, Toko H, Honda F, Abe S, Takahashi H, Yagishita M, Hagiwara S, Ohyama A, Kondo Y, Nakano K, Tanaka Y, Shimizu T, Nakamura H, Kawakami A, Fujieda Y, Atsumi T, Suzuki Y, Kawano M, Nishina N, Kaneko Y, Takeuchi T, Kobayashi H, Takei M, Ogasawara M, Tamura N, Takasaki Y, Yokota K, Akiyama Y, Mimura T, Murakami K, Mimori T, Ohshima S, Azuma N, Sano H, Nishiyama S, Matsumoto I, Sumida T. Tsuboi H, et al. Among authors: nakano k. Mod Rheumatol. 2023 Jan 3;33(1):160-168. doi: 10.1093/mr/roac011. Mod Rheumatol. 2023. PMID: 35134994
Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.
Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, Nakano K, Nakayamada S, Yamaoka K, Sawamura F, Saito K. Tanaka Y, et al. Among authors: nakano k. Ann Rheum Dis. 2015 Feb;74(2):389-95. doi: 10.1136/annrheumdis-2013-204016. Epub 2013 Nov 28. Ann Rheum Dis. 2015. PMID: 24288014 Free PMC article. Clinical Trial.
Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: a multi-center retrospective cohort study.
Saito R, Tanaka M, Ito H, Kuramoto N, Fujii T, Saito S, Kaneko Y, Nakano K, Saito K, Takada H, Sugimoto N, Sasaki S, Harigai M, Suzuki Y. Saito R, et al. Among authors: nakano k. Mod Rheumatol. 2022 Jan 5;32(1):50-58. doi: 10.1080/14397595.2020.1866837. Mod Rheumatol. 2022. PMID: 33336615
2,960 results